I hate being on the sidelines for a runup in a stock on my watch list, but today I was on the sidelines- until the end of the day.
Before today, I had no confidence that NovaDel's Zolpimist, a short term Oral Spray treatment for Insomnia, would receive approval from the FDA, hence my not investing in the company, but today the FDA did, in fact, approve Zolpimist leading to the sharp rise in share price.
The temptation to chase a stock is there as you're watching it go higher, but NVD's jump did not last long and the stock price slowly retreated back down throughout the second half of the trading day before closing at 46 cents. In my opinion, the drop was most likely due to the big boys wanting to load up with as many cheap shares as they can get.
In a more stable market, this stock may have seen nearly two bucks today, but with market conditions as they are, drug approvals mean nothing- at least not in the short term. I've watched the stock price for EPCT (Epicept) and AGEN (Antigenics) drop after receiving approvals this year, so it was no surprise to see NVD also drop back down. NVD, however, is the only one of these three that has a drug approved in the USA; Epicept has Ceplene approved in Europe and Antigenics has Oncophage approved in Russia.
I took advantage of the afternoon drop and bought in at fifty cents. NovaDel now has two FDA approved drugs; the aforementioned Zolpimist and the previously approved Nitromist with six other drug candidates (or modified dosings of current drugs) in early stages of development, all using NovaDel's proprietary NovaMist oral spray technology.
A company with two approved drugs equals a good buy (in my opinion), especially in this depressed market.
In the long run, NVD (as well as EPCT and AGEN) should rebound when the market rebounds, but a short term run is also possible pending any news of a partnership.
Caveat: There's a million stock market bargains out there right now that may be a lot safer than a small biotech with a just-approved drug. However, these biotechs with recently approved drugs could outperform the market (in terms of percentage gain) when the rebound occurs.

STOCK NOTES:
EPCT, Epicept: After recently receiving approval to market Ceplene in Europe, Epicept is preparing to file a New Drug Application that will allow the company to market Ceplene in Canada, according to recent Press Releases.
With an approved drug and the potential for a partnership announcement early in 2009, I still believe that EPCT is a great buy- especially when it is trading for sixty cents.
CPST, Capstone Turbine: I still love CPST and their microturbine technology. We got a gift, in my opinion, when the stock price dropped to about sixty cents a few weeks ago, and I took advantage of the drop by placing trades at 88, 78 and 68 cents in an attempt to average down.
CPST is again trading for over a dollar, but I'll be taking advantage of all dips below a buck in this crazy market.
The orders and contracts are rolling in for Capstone, now its time to see this company turn a profit. We're likely still a few years away from that, however.
VFC's Bear Market Stock Picks Part I
VFC's Bear Market Picks Part II
VFC's Bear Market Picks Part III
VFC's Bear Market Non Picks Part
VFC's Stock Updates
VFC's Bear Market Picks Part IV; CRYP, CSUH.OB
VFC's Biotech Picks
VFC's Quarterly Updates
INSM Update, IPLEX Back In Action
GET THE LADY SHOPPING! TAKE ADVANTAGE OF HER ROOM'S 70% SEASON CLOSEOUT DISCOUNTS!








